The Middle East & Africa NGS Market is expected to register a CAGR of 11.1% from 2024 to 2031 to reach $ 356.5 million by 2031. Next Generation Sequencing (NGS) is a genome sequencing technology usually used for research purposes and applied in clinical diagnostics. NGS determines the order of nucleotides in the entire genomes or targeted regions of DNA or RNA. It is used for various research and clinical applications such as disease diagnosis, prognosis, therapeutic decisions, follow-up of patients, drug discovery, biomarker research, and environmental testing. Also, its massive parallel sequencing capacity offers new opportunities for personalized or precision medicine.
The growth of the Middle East & Africa NGS market can be attributed to various factors, including the surge in genome sequencing programs, technological advancements in sequencing procedures, decreasing costs of genome sequencing, and a rise in cancer prevalence, and the expanding applications of NGS in cancer treatment and research. However, the high costs of NGS systems and consumables and the availability of alternative technologies restrain the market's growth.
The rising adoption of bioinformatics and genomic data management solutions, as well as collaborations and partnerships to support next-generation sequencing, are expected to create market growth opportunities. However, a lack of skilled professionals and a lack of standardization pose a significant challenge to the market's growth.
With rapid advancements in NGS technology, various organizations & governments are actively undertaking initiatives for genomic sequencing projects. These initiatives aim to improve early disease diagnosis. Some of the initiatives are as follows:
According to The National (a local daily newspaper), in March 2023, the UAE President launched the National genome strategy. This launch aims to map the DNA of every citizen to provide personalized care to every citizen in the country.
Click here to: Get Free Sample Pages of this Report
Next Generation Sequencing (NGS) is a technology used to sequence the orientation of nucleotides in genetic material. This technology enables the sequencing of DNA or RNA more quickly and at a lower cost compared to Sanger sequencing. Continuous developments in NGS technology are revolutionizing the field of personalized medicine, genetic diseases, and clinical diagnostics by providing the capability to sequence multiple individuals with a variable genetic orientation simultaneously. Various organizations are focusing on partnerships, collaborations, and expansion to increase genetic testing and support next-generation sequencing. For instance:
Thus, increasing collaborations and partnerships among vendors are expected to accelerate the adoption of NGS technology in the Middle East & Africa.
Among the offerings, in 2024, the consumables segment is expected to account for the largest share of the Middle East & Africa NGS market. The increasing use of sequencing reagents and kits for diagnostic procedures has majorly attributed to the large share of this segment in the Middle East & Africa NGS market. Additionally, factors such as increasing genome mapping projects, rising preference for NGS-based diagnostic tests, and increasing awareness about the advantages of NGS for diagnostic and research purposes are supporting the growth of the segment.
Among sequencing types, in 2024, the targeted genome sequencing segment is expected to account for the largest share of the Middle East & Africa NGS market. Targeted genome sequencing significantly reduces the cost per sample over whole genome shotgun sequencing by enabling sequencing of only the desired regions of a genome. Furthermore, the early success of targeted sequencing methods has created a rapidly growing demand for targeted sequencing in areas such as cancer, human genetic disease, and the validation of genome-wide association studies. These factors have increased the adoption of targeted genome sequencing, contributing to the large market share of this segment.
Among the technologies, in 2024, the sequencing by synthesis segment is expected to account for the largest share of the Middle East & Africa NGS market. The large share of this segment is primarily attributed to the high accuracy of this technology in DNA sequencing, its highest yield of error-free throughput, and the increasing incorporation of this technology in NGS products.
Among the applications, in 2024, the research applications segment is expected to account for the largest share of the Middle East & Africa NGS market. The large market share of this segment is attributed to the rising adoption of sequencing-based tests in laboratories, growing research activities by pharmaceutical & biotechnology companies, increasing applications of NGS, growing demand for personalized medicines, and increasing availability of NGS instruments at lower costs are some of the major factors attributed to the large share of this segment in the NGS market.
Among the end users, in 2024, the pharmaceutical & biotechnology companies’ segment is expected to account for the largest share of the Middle East & Africa NGS market. The large market share of this segment is attributed to factors such as the increasing adoption of advanced technologies for research purposes, increasing research for drug discovery with widening NGS applications, and the rising incidence of chronic diseases. For instance, according to GLOBOCAN, in 2022, 5,526 people were diagnosed with cancer in the United Arab Emirates. This number is projected to reach 7,328 by 2030. Further, in 2022, 28,113 people were diagnosed with cancer in Saudi Arabia. This number is projected to reach 39,900 by 2030.
In 2024, Saudi Arabia is expected to account for the largest share of the Middle East & Africa NGS market. Saudi Arabia’s significant market share can be attributed to the growing adoption of NGS technology among healthcare professionals for the treatment of diseases and an increasing number of sequencing projects such as the Saudi Human Genome Programme, The Saudi Biobank, and Majeen.
The report includes a competitive landscape based on an extensive assessment of the key growth strategies adopted by leading market players over the past three to four years. The key players profiled in the Middle East & Africa NGS market report are Thermo Fisher Scientific Inc. (U.S.), Illumina, Inc. (U.S.), Qiagen N.V. (Netherlands), F. Hoffmann-La Roche Ltd (Switzerland), PerkinElmer, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Danaher Corporation (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Oxford Nanopore Technologies Plc. (U.K.), 10X Genomics, Inc. (U.S.), and Pacific Biosciences of California Inc. (U.S.).
|
Particulars |
Details |
|
Number of Pages |
~150 |
|
Format |
|
|
Forecast Period |
2024-2031 |
|
Base Year |
2023 |
|
CAGR |
11.1% |
|
Estimated Market Size (Value) |
$ 356.5 million by 2031 |
|
Segments Covered |
By Offering
By Sequencing Type
By Technology
By Application
By End User
|
|
Countries Covered |
Middle East & Africa (United Arab Emirates, Saudi Arabia, Egypt, South Africa, Qatar, and Rest of Middle East & Africa) |
|
Key Companies |
Thermo Fisher Scientific Inc. (U.S.), Illumina, Inc. (U.S.), Qiagen N.V. (Netherlands), F. Hoffmann-La Roche Ltd (Switzerland), PerkinElmer, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Danaher Corporation (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Oxford Nanopore Technologies Plc. (U.K.), 10X Genomics, Inc. (U.S.), and Pacific Biosciences of California Inc. (U.S.). |
This study offers a detailed assessment of the Middle East & Africa NGS market, including the market sizes and forecasts for various segmentations like offering, sequencing type, technology, application, and end user. This report also involves the value analysis of various segments and sub-segments of NGS at the country level.
The Middle East & Africa NGS market is projected to reach $356.5 million by 2031, at a CAGR of 11.1% during the forecast period.
Among the offerings, in 2024, the consumables segment is expected to account for the largest share of the Middle East & Africa market. The large market share of this segment is attributed to the recurring use of consumables, increasing genome mapping projects, rising preference for NGS-based diagnostic tests, and increasing awareness about the advantages of NGS for diagnostic and research purposes.
In 2024, the targeted genome sequencing segment is expected to account for the largest share of the Middle East & Africa NGS market. The large market share of this segment is attributed to its low sequencing costs compared to other sequencing technologies, increased sensitivity in variant calling, and advancements in targeted genome sequencing technologies.
The growth of the Middle East & Africa NGS market can be attributed to various factors, including the growth of the Middle East & Africa NGS market can be attributed to various factors, including the surge in genome sequencing programs, technological advancements in sequencing procedures, decreasing costs of genome sequencing, a rise in genetic diseases and cancer prevalence, and the expanding application of NGS in cancer treatment and research.
The rising adoption of bioinformatics and genomic data management solutions, as well as collaborations and partnerships to support next-generation sequencing, are expected to create market growth opportunities.
The key players profiled in the Middle East & Africa NGS market report are Thermo Fisher Scientific Inc. (U.S.), Illumina, Inc. (U.S.), Qiagen N.V. (Netherlands), F. Hoffmann-La Roche Ltd (Switzerland), PerkinElmer, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Danaher Corporation (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Oxford Nanopore Technologies Plc. (U.K.), 10X Genomics, Inc. (U.S.), and Pacific Biosciences of California Inc. (U.S.).
This report provides pre & post COVID-19 market estimates.
1. Introduction
1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency & Limitations
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Approach
2.2. Process of Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders from the Industry
2.3. Market Sizing & Forecast
2.3.1. Market Size Estimation Approach
2.3.2. Growth Forecast Approach
2.4. Assumptions for the Study
3. Executive Summary
4. Market Insights
4.1. Overview
4.2. Drivers
4.2.1. Surge in Genome Sequencing Programs
4.2.2. Technological Advancements in Sequencing Procedures
4.2.3. Declining Costs of Genome Sequencing
4.2.4. Rising Cancer Prevalence and Increasing Application of NGS in Cancer Treatment and Research
4.3. Restraints
4.3.1. High Costs of NGS Systems and Consumables
4.3.2. Availability of Alternative Technologies
4.4. Opportunities
4.4.1. Partnerships and Collaboration to Support Next-Generation Sequencing
4.4.2. Rising Adoption of Bioinformatics and Genomic Data Management Solutions
4.5. Challenges
4.5.1. Lack of Standardization
4.5.2. Lack of Skilled Professionals
4.6. Factor Analysis
4.7. Pricing Analysis
4.8. Regulatory Analysis
4.9. Adjacent Market Analysis
5. Middle East & Africa NGS Market Assessment - by Offering
5.1. Overview
5.2. Consumables
5.2.1. Sample Preparation Consumables
5.2.1.1. DNA Extraction and Amplification
5.2.1.2. Library Preparation & Target Enrichment
5.2.1.3. Quality Control
5.2.2. Other Consumables
5.3. NGS Platforms/Instruments
5.4. Software
5.5. Services
6. Middle East & Africa NGS Market Assessment - by Sequencing Type
6.1. Overview
6.2. Targeted Genome Sequencing
6.3. Whole Genome Sequencing
6.4. Whole Exome Sequencing
6.5. Other Sequencing Types
7. Middle East & Africa NGS Market Assessment - by Technology
7.1. Overview
7.2. Sequencing by Synthesis
7.3. Ion Semiconductor Sequencing
7.4. Single-molecule Real-time Sequencing (SMRT)
7.5. Nanopore Sequencing
7.6. DNA nanoball Sequencing
8. Middle East & Africa NGS Market Assessment - by Application
8.1. Overview
8.2. Research Applications
8.2.1. Drug Discovery
8.2.2. Agriculture & Animal Research
8.2.3. Other Research Applications
8.3. Clinical Applications
8.3.1. Reproductive Health
8.3.2. Oncology
8.3.3. Infectious Diseases
8.3.4. Other Clinical Applications
9. Middle East & Africa NGS Market Assessment - by End User
9.1. Overview
9.2. Pharmaceutical & Biotechnology Companies
9.3. Hospitals and Diagnostic Laboratories
9.4. Academic Institutes and Research Centers
9.5. Other End Users
10. Middle East & Africa NGS Market Assessment - by Country
10.1. Overview
10.2. United Arab Emirates
10.3. Qatar
10.4. Saudi Arabia
10.5. Egypt
16.6. South Africa
10.7. Rest of Middle East & Africa
11. Competition Analysis
11.1. Overview
11.2. Key Growth Strategies
11.3. Competitive Benchmarking
11.4. Competitive Dashboard
11.4.1. Industry Leaders
11.4.2. Market Differentiators
11.4.3. Vanguards
11.4.4. Emerging Companies
11.5. Market Share Analysis/Market Rankings, By Key Players (2023)
12. Company Profiles (Business Overview, Financial Overview, Product Portfolio, and Strategic Developments)
12.1. Thermo Fisher Scientific Inc.
12.2. Illumina, Inc.
12.3. Qiagen N.V.
12.4. F. Hoffmann-La Roche Ltd.
12.5. PerkinElmer, Inc.
12.6. Agilent Technologies, Inc.
12.7. Pacific Biosciences of California Inc.
12.8. Danaher Corporation
12.9. Oxford Nanopore Technologies Plc.
12.10. 10X Genomics, Inc.
12.11. Bio-Rad Laboratories, Inc.
(Note: SWOT Analysis of the Top 5 Companies Will Be Provided)
13. Appendix
13.1. Available Customization
13.2. Related Reports
List of Tables
Table 1 Middle East & Africa NGS Market, by Offering, 2022–2031 (USD Million)
Table 2 Middle East & Africa NGS Consumables Market, by Type, 2022–2031 (USD Million)
Table 3 Middle East & Africa NGS Consumables Market, by Country/Region, 2022–2031 (USD Million)
Table 4 Middle East & Africa NGS Sample Preparation Consumables Market, by Type, 2022–2031 (USD Million)
Table 5 Middle East & Africa NGS Sample Preparation Consumables Market, by Country/Region, 2022–2031 (USD Million)
Table 6 Middle East & Africa NGS DNA Extraction and Amplification Market, by Country/Region, 2022–2031 (USD Million)
Table 7 Middle East & Africa NGS Library Preparation & Target Enrichment Market, by Country/Region, 2022–2031 (USD Million)
Table 8 Middle East & Africa NGS Quality Control Market, by Country/Region, 2022–2031 (USD Million)
Table 9 Middle East & Africa NGS Other Consumables Market, by Country/Region, 2022–2031 (USD Million)
Table 10 Middle East & Africa NGS Platforms/Instruments Market, by Country/Region, 2022–2031 (USD Million)
Table 11 Middle East & Africa NGS Software Market, by Country/Region, 2022–2031 (USD Million)
Table 12 Middle East & Africa NGS Services Market, by Country/Region, 2022–2031 (USD Million)
Table 13 Middle East & Africa NGS Market, by Sequencing Type, 2022–2031 (USD Million)
Table 14 Middle East & Africa NGS Market for Targeted Genome Sequencing, by Country/Region, 2022–2031 (USD Million)
Table 15 Middle East & Africa NGS Market for Whole Genome Sequencing, by Country/Region, 2022–2031 (USD Million)
Table 16 Middle East & Africa NGS Market for Whole Exome Sequencing, by Country/Region, 2022–2031 (USD Million)
Table 17 Middle East & Africa NGS Market for Other Sequencing Types, by Country/Region, 2022–2031 (USD Million)
Table 18 Middle East & Africa NGS Market, by Technology, 2022–2031 (USD Million)
Table 19 Middle East & Africa NGS Market for Sequencing by Synthesis, by Country/Region, 2022–2031 (USD Million)
Table 20 Middle East & Africa NGS Market for Ion Semiconductor Sequencing, by Country/Region, 2022–2031 (USD Million)
Table 21 Middle East & Africa NGS Market for Single-molecule Real-time Sequencing (SMRT), by Country/Region, 2022–2031 (USD Million)
Table 22 Middle East & Africa NGS Market for Nanopore Sequencing, by Country/Region, 2022–2031 (USD Million)
Table 23 Middle East & Africa NGS Market for DNA nanoball sequencing, by Country/Region, 2022–2031 (USD Million)
Table 24 Middle East & Africa NGS Market, by Application, 2022–2031 (USD Million)
Table 25 Middle East & Africa NGS Market for Research Applications, by Type, 2022–2031 (USD Million)
Table 26 Middle East & Africa NGS Market for Research Applications, by Country/Region, 2022–2031 (USD Million)
Table 27 Middle East & Africa NGS Market for Drug Discovery, by Country/Region, 2022–2031 (USD Million)
Table 28 Middle East & Africa NGS Market for Agriculture & Animal Research, by Country/Region, 2022–2031 (USD Million)
Table 29 Middle East & Africa NGS Market for Other Research Applications, by Country/Region, 2022–2031 (USD Million)
Table 30 Middle East & Africa NGS Market for Clinical Applications, by Type, 2022–2031 (USD Million)
Table 31 Middle East & Africa NGS Market for Reproductive Health Diagnosis, by Country/Region, 2022–2031 (USD Million)
Table 32 Middle East & Africa NGS Market for Oncology, by Country/Region, 2022–2031 (USD Million)
Table 33 Middle East & Africa NGS Market for Infectious Diseases, by Country/Region, 2022–2031 (USD Million)
Table 34 Middle East & Africa NGS Market for Other Clinical Applications, by Country/Region, 2022–2031 (USD Million)
Table 35 Middle East & Africa: NGS Market, by End User, 2022–2031 (USD Million)
Table 36 Middle East & Africa NGS Market for Hospitals and Diagnostic Laboratories, by Country/Region, 2022–2031 (USD Million)
Table 37 Middle East & Africa NGS Market for Pharmaceutical & Biotechnology Companies, by Country/Region, 2022–2031 (USD Million)
Table 38 Middle East & Africa NGS Market for Academic Institutes & Research Centers, by Country/Region, 2022–2031 (USD Million)
Table 39 Middle East & Africa NGS Market for Other End Users, by Country/Region, 2022–2031 (USD Million)
Table 40 Middle East & Africa: NGS Market, by Country/Region, 2022–2031 (USD Million)
Table 41 United Arab Emirates: NGS Market, by Offering, 2022–2031 (USD Million)
Table 42 United Arab Emirates: NGS Consumables Market, by Type, 2022–2031 (USD Million)
Table 43 United Arab Emirates: NGS Sample Preparation Consumables Market, by Type, 2022–2031 (USD Million)
Table 44 United Arab Emirates: NGS Market, by Sequencing Type, 2022–2031 (USD Million)
Table 45 United Arab Emirates: NGS Market, by Technology, 2022–2031 (USD Million)
Table 46 United Arab Emirates: NGS Market, by Application, 2022–2031 (USD Million)
Table 47 United Arab Emirates: NGS Market for Clinical Applications, by Type, 2022–2031 (USD Million)
Table 48 United Arab Emirates: NGS Market for Research Applications, by Type, 2022–2031 (USD Million)
Table 49 United Arab Emirates: NGS Market, by End User, 2022–2031 (USD Million)
Table 50 Qatar: NGS Market, by Offering, 2022–2031 (USD Million)
Table 51 Qatar: NGS Consumables Market, by Type, 2022–2031 (USD Million)
Table 52 Qatar: NGS Sample Preparation Consumables Market, by Type, 2022–2031 (USD Million)
Table 53 Qatar: NGS Market, by Sequencing Type, 2022–2031 (USD Million)
Table 54 Qatar: NGS Market, by Technology, 2022–2031 (USD Million)
Table 55 Qatar: NGS Market, by Application, 2022–2031 (USD Million)
Table 56 Qatar: NGS Market for Clinical Applications, by Type, 2022–2031 (USD Million)
Table 57 Qatar: NGS Market for Research Applications, by Type, 2022–2031 (USD Million)
Table 58 Qatar: NGS Market, by End User, 2022–2031 (USD Million)
Table 59 Saudi Arabia: NGS Market, by Offering, 2022–2031 (USD Million)
Table 60 Saudi Arabia: NGS Consumables Market, by Type, 2022–2031 (USD Million)
Table 61 Saudi Arabia: NGS Sample Preparation Consumables Market, by Type, 2022–2031 (USD Million)
Table 62 Saudi Arabia: NGS Market, by Sequencing Type, 2022–2031 (USD Million)
Table 63 Saudi Arabia: NGS Market, by Technology, 2022–2031 (USD Million)
Table 64 Saudi Arabia: NGS Market, by Application, 2022–2031 (USD Million)
Table 65 Saudi Arabia: NGS Market for Clinical Applications, by Type, 2022–2031 (USD Million)
Table 66 Saudi Arabia: NGS Market for Research Applications, by Type, 2022–2031 (USD Million)
Table 67 Saudi Arabia: NGS Market, by End User, 2022–2031 (USD Million)
Table 68 Egypt: NGS Market, by Offering, 2022–2031 (USD Million)
Table 69 Egypt: NGS Consumables Market, by Type, 2022–2031 (USD Million)
Table 70 Egypt: NGS Sample Preparation Consumables Market, by Type, 2022–2031 (USD Million)
Table 71 Egypt: NGS Market, by Sequencing Type, 2022–2031 (USD Million)
Table 72 Egypt: NGS Market, by Technology, 2022–2031 (USD Million)
Table 73 Egypt: NGS Market, by Application, 2022–2031 (USD Million)
Table 74 Egypt: NGS Market for Clinical Applications, by Type, 2022–2031 (USD Million)
Table 75 Egypt: NGS Market for Research Applications, by Type, 2022–2031 (USD Million)
Table 76 Egypt: NGS Market, by End User, 2022–2031 (USD Million)
Table 77 South Africa: NGS Market, by Offering, 2022–2031 (USD Million)
Table 78 South Africa: NGS Consumables Market, by Type, 2022–2031 (USD Million)
Table 79 South Africa: NGS Sample Preparation Consumables Market, by Type, 2022–2031 (USD Million)
Table 80 South Africa: NGS Market, by Sequencing Type, 2022–2031 (USD Million)
Table 81 South Africa: NGS Market, by Technology, 2022–2031 (USD Million)
Table 82 South Africa: NGS Market, by Application, 2022–2031 (USD Million)
Table 83 South Africa: NGS Market for Clinical Applications, by Type, 2022–2031 (USD Million)
Table 84 South Africa: NGS Market for Research Applications, by Type, 2022–2031 (USD Million)
Table 85 South Africa: NGS Market, by End User, 2022–2031 (USD Million)
Table 86 Rest of Middle East & Arica: NGS Market, by Offering, 2022–2031 (USD Million)
Table 87 Rest of Middle East & Arica: NGS Consumables Market, by Type, 2022–2031 (USD Million)
Table 88 Rest of Middle East & Arica: NGS Sample Preparation Consumables Market, by Type, 2022–2031 (USD Million)
Table 89 Rest of Middle East & Arica: NGS Market, by Sequencing Type, 2022–2031 (USD Million)
Table 90 Rest of Middle East & Arica: NGS Market, by Technology, 2022–2031 (USD Million)
Table 91 Rest of Middle East & Arica: NGS Market, by Application, 2022–2031 (USD Million)
Table 92 Rest of Middle East & Arica: NGS Market for Clinical Applications, by Type, 2022–2031 (USD Million)
Table 93 Rest of Middle East & Arica: NGS Market for Research Applications, by Type, 2022–2031 (USD Million)
Table 94 Rest of Middle East & Arica: NGS Market, by End User, 2022–2031 (USD Million)
Table 95 Recent Developments, by Company, 2020–2024
List of Figures
Figure 1 Research Process
Figure 2 Key Secondary Sources
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply-side & Demand-side)
Figure 6 Market Size Estimation
Figure 7 Middle East & Africa NGS Market, by Offering, 2024 VS.2031 (USD Million)
Figure 8 Middle East & Africa NGS Market, by Sequencing Type, 2024 VS.2031 (USD Million)
Figure 9 Middle East & Africa NGS Market, by Technology, 2024 VS.2031 (USD Million)
Figure 10 Middle East & Africa NGS Market, by Application, 2024 VS.2031 (USD Million)
Figure 11 Middle East & Africa NGS Market, by End User, 2024 VS.2031 (USD Million)
Figure 12 Middle East & Africa NGS Market, by Country/Region
Figure 13 Impact Analysis: Middle East & Africa NGS Market
Figure 14 Middle East & Africa NGS Market, by Offering, 2024 VS.2031 (USD Million)
Figure 15 Middle East & Africa NGS Market, by Sequencing Type, 2024 VS.2031 (USD Million)
Figure 16 Middle East & Africa NGS Market, by Technology, 2024 VS.2031 (USD Million)
Figure 17 Middle East & Africa NGS Market, by Application, 2024 VS.2031 (USD Million)
Figure 18 Middle East & Africa NGS Market, by End User, 2024 VS.2031 (USD Million)
Figure 19 Middle East & Africa NGS Market, by Country/Region, 2024 VS.2031 (USD Million)
Figure 20 Middle East & Africa NGS Market Snapshot
Figure 21 Key Growth Strategies Adopted by Leading Players (2020–2024)
Figure 22 Middle East & Africa NGS Market: Vendor Dashboard
Figure 23 Middle East & Africa NGS Market: Competitive Benchmarking, by Offering
Figure 24 Middle East & Africa NGS Market: Competitive Benchmarking, by Sequencing Type
Figure 25 Market Share Analysis: Middle East & Africa NGS Market (2023)
Figure 26 Thermo Fisher Scientific, Inc.: Financial Snapshot, 2023
Figure 27 Illumina, Inc.: Financial Snapshot, 2023
Figure 28 Qiagen N.V.: Financial Snapshot, 2023
Figure 29 F. Hoffmann-La Roche Ltd: Financial Snapshot, 2023
Figure 30 PerkinElmer, Inc.: Financial Snapshot, 2023
Figure 31 Agilent Technologies, Inc.: Financial Snapshot, 2023
Figure 32 Pacific Biosciences of California, Inc.: Financial Snapshot, 2023
Figure 33 Danaher Corporation: Financial Snapshot, 2023
Figure 34 Oxford Nanopore Technologies Plc.: Financial Snapshot, 2023
Figure 35 10X Genomics, Inc.: Financial Snapshot, 2023
Figure 36 Pacific Biosciences of California Inc.: Financial Snapshot, 2023
This report provides pre & post COVID-19 market estimates.
This report provides pre & post COVID-19 market estimates.
Published Date: Jan-2024
Published Date: Dec-2023
Published Date: Aug-2023
